Full Spectrum CBD Topicals: The Complete Clinical Picture
A practitioner-level guide to full spectrum hemp extract, the entourage effect, transdermal cannabinoid delivery, and how Kannaco formulations compare — with the science to back every claim.
Key Terminology
Definitions Every Practitioner Should Know
Clinical definitions for the core terminology used in cannabinoid science and topical formulation — with practitioner-relevant context for each.
Full Spectrum Extract
An extract that retains all naturally occurring compounds from the hemp plant — cannabinoids, terpenes, flavonoids, and trace THC (below 0.3% by federal law). The full chemical profile is preserved.
Preferred when the goal is maximum phytochemical complexity. The trace THC content activates CB1 receptors synergistically with CBD, potentially enhancing overall efficacy.
Broad Spectrum Extract
An extract that retains most hemp plant compounds but has had THC specifically removed through additional processing. THC is below detectable limits but not guaranteed at 0.0%.
A middle option for patients who want multi-compound benefits but have concerns about THC. Less common in topical formulations than full spectrum or isolate.
CBD Isolate
Pure cannabidiol in crystalline form — all other compounds removed. 99%+ CBD by weight with 0.0% THC.
The most controlled formulation option. Allows precise dosing and eliminates all THC exposure. Used in Kannaco Pro Cream and Pro Roll-On paired with CBG isolate.
CBG (Cannabigerol)
A non-psychoactive cannabinoid sometimes called the 'mother cannabinoid' because other cannabinoids are biosynthesized from its precursor form (CBGA). CBG interacts with both CB1 and CB2 receptors.
CBG has demonstrated affinity for CB2 receptors in peripheral tissue and is associated with anti-inflammatory activity. The 1:1 CBD:CBG ratio in Kannaco Pro formulas is designed to leverage both receptor pathways simultaneously.
The Entourage Effect
The hypothesis, first proposed by Raphael Mechoulam, that cannabinoids and terpenes work synergistically — producing effects greater than any single compound in isolation.
Supports the rationale for full spectrum formulations. When recommending the CBD Cooling Cream, this concept explains why the full plant extract may provide a different experience than isolate-based products.
Endocannabinoid System (ECS)
A biological signaling system present in all mammals, consisting of endocannabinoids (produced by the body), cannabinoid receptors (CB1 and CB2), and metabolic enzymes. Regulates homeostasis across multiple physiological systems.
The ECS is the primary mechanism through which topical cannabinoids exert their effects. Understanding this system is foundational to explaining CBD topicals to patients.
CB1 Receptors
Cannabinoid receptor type 1. Primarily located in the central nervous system but also present in peripheral nerves, skin keratinocytes, and subcutaneous tissue. Activated by THC and some terpenes.
Relevant to topical application: CB1 receptors in peripheral sensory neurons may modulate nociceptive signaling locally without CNS involvement when activated by topical cannabinoids.
CB2 Receptors
Cannabinoid receptor type 2. Primarily located in immune cells, peripheral tissue, and the skin. Activated by CBD, CBG, and endocannabinoids like 2-AG. Associated with anti-inflammatory signaling.
The primary target for topical CBD and CBG. High CB2 receptor density in skin and subcutaneous tissue makes topical application an efficient delivery route for localized cannabinoid effects.
Topical vs. Transdermal Delivery
Topical delivery targets receptors in the skin and underlying tissue without meaningful systemic absorption. Transdermal delivery uses penetration enhancers to drive compounds through the skin barrier into the bloodstream.
All Kannaco products are topical, not transdermal. This distinction is clinically important: topical application does not produce detectable blood levels of cannabinoids, which is why drug test safety is achievable with the Pro formulas.
Mechanism of Action
The Science Behind Topical Cannabinoid Delivery
Three foundational mechanisms that explain why full spectrum topicals work — and how to communicate them to your patients and team.
The Endocannabinoid System in Peripheral Tissue
The endocannabinoid system (ECS) is a ubiquitous signaling network present in all mammalian tissue, including the skin. The skin expresses both CB1 and CB2 receptors in keratinocytes, sebocytes, hair follicle cells, sensory nerve fibers, and mast cells. This peripheral ECS operates largely independently of the central nervous system, making it an accessible target for topical delivery.
When a topical cannabinoid is applied, it interacts with these peripheral receptors without requiring systemic absorption. CB2 receptor activation in skin immune cells modulates cytokine release and inflammatory signaling. CB1 receptor activation in peripheral sensory neurons can modulate nociceptive signaling locally. The result is localized activity without psychoactive or systemic effects.
Bíró T. et al. (2009) "The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities." Trends in Pharmacological Sciences, 30(8), 411–420.
The Entourage Effect: Synergistic Phytochemistry
Full spectrum hemp extract contains over 100 identified phytocannabinoids alongside terpenes, flavonoids, and fatty acids. The entourage effect — first described by Raphael Mechoulam and Shimon Ben-Shabat in 1998 — proposes that these compounds act synergistically, with the combined effect exceeding what any single isolated compound could produce.
In the context of topical application, this means the terpenes in a full spectrum extract (such as beta-caryophyllene, which is itself a CB2 agonist) may enhance the activity of CBD and other cannabinoids at peripheral receptors. Flavonoids like quercetin and kaempferol contribute additional anti-inflammatory activity through non-cannabinoid pathways. The result is a more complex and potentially more effective biological response than isolate-based formulations.
Russo E.B. (2011) "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects." British Journal of Pharmacology, 163(7), 1344–1364.
Topical vs. Transdermal: Understanding the Delivery Distinction
Topical and transdermal are not interchangeable terms. Topical delivery targets receptors in the epidermis, dermis, and subcutaneous tissue — the compound does not cross the skin barrier in meaningful quantities and does not enter systemic circulation. Transdermal delivery uses penetration enhancers (such as DMSO or specific fatty acid carriers) to drive compounds through the skin barrier and into the bloodstream.
All Kannaco products are formulated for topical delivery. The carrier system — including arnica, menthol, camphor, and the lipid-rich base — is designed to optimize localized receptor engagement, not systemic absorption. This is the mechanism that makes topical CBD safe for patients concerned about drug testing: no systemic absorption means no detectable blood levels of cannabinoids.
Lodzki M. et al. (2003) "Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model." Journal of Controlled Release, 93(3), 377–387.
Ingredient Science
Every Ingredient. Every Role.
A practitioner-level breakdown of the key active and functional ingredients across the Kannaco topical line — with mechanism, role, and clinical relevance for each.
CBD (Cannabidiol)
Primary cannabinoid active — CB1 and CB2 receptor modulator
CBD is a partial agonist at CB1 and CB2 receptors and an allosteric modulator of multiple receptor types including TRPV1 and 5-HT1A. In peripheral tissue, CB2 activation modulates cytokine release and inflammatory signaling. TRPV1 desensitization contributes to the cooling/warming sensory arc.
CBG (Cannabigerol)
Secondary cannabinoid active — CB2 agonist, anti-inflammatory
CBG demonstrates higher CB2 receptor affinity than CBD in some models. CB2 activation in skin immune cells (mast cells, macrophages) modulates pro-inflammatory cytokine release. The 1:1 CBD:CBG ratio in Pro formulas is designed to leverage both CB1 and CB2 pathways simultaneously for a broader receptor engagement profile.
Full Spectrum Hemp Extract
Entourage effect carrier — phytocannabinoid + terpene complex
Full spectrum extract retains all naturally occurring hemp compounds including minor cannabinoids (CBN, CBC, CBDV), terpenes (beta-caryophyllene, linalool, myrcene), and flavonoids (quercetin, kaempferol). Beta-caryophyllene is itself a selective CB2 agonist. This phytochemical complexity is the basis of the entourage effect hypothesis.
Arnica Montana Flower Extract
Anti-inflammatory botanical — bruising, swelling, post-exertion recovery
Arnica contains sesquiterpene lactones (helenalin, dihydrohelenalin) that inhibit NF-κB activation and reduce pro-inflammatory cytokine production. Topical arnica has demonstrated efficacy in reducing post-exercise muscle soreness and bruising in multiple RCTs. Works synergistically with cannabinoids at peripheral CB2 receptor sites.
Menthol
TRPM8 agonist — cooling sensation, counterirritant
Menthol activates TRPM8 (transient receptor potential melastatin 8) cold receptors in peripheral sensory neurons, producing the characteristic cooling sensation without actual temperature change. As a counterirritant, it modulates nociceptive signaling through the gate control mechanism. The cooling onset in all three Kannaco formulas is primarily driven by menthol.
Camphor
TRPV1 and TRPM8 modulator — warming sensation, counterirritant
Camphor activates TRPV1 (heat receptor) at low concentrations and TRPM8 (cold receptor) at higher concentrations, producing the characteristic warming sensation that follows the menthol cooling phase. This biphasic sensory arc — cooling onset followed by warming mid-phase — is a hallmark of all three Kannaco formulas and is clinically associated with the counterirritant mechanism of action.
Frequently Asked Questions
Full Spectrum CBD — Clinical FAQ
The most common questions practitioners ask about full spectrum formulations, the entourage effect, and how Kannaco products compare.
Full spectrum retains all naturally occurring hemp compounds — cannabinoids, terpenes, flavonoids, and trace THC. This phytochemical complexity is the basis of the entourage effect hypothesis: the compounds may work synergistically, producing effects greater than any single compound in isolation. Isolate formulations contain only the specific cannabinoids selected (in Kannaco's case, CBD and CBG), with all other compounds removed. Both are effective
No. Topical application does not produce systemic absorption in meaningful quantities. The trace THC in full spectrum hemp extract (below 0.3% by federal law) does not reach the bloodstream through topical use, and therefore does not produce psychoactive effects. Patients can be reassured that topical CBD products — including full spectrum formulas — do not cause intoxication.
The Cooling Cream is formulated for general recovery and patients who want the full phytochemical profile of the hemp plant. The Pro Cream and Pro Roll-On are formulated for patients who require 0.0% THC — athletes subject to drug testing, patients with strict zero-tolerance policies, or practitioners who prefer a controlled, precisely defined cannabinoid profile. The 1:1 CBD:CBG isolate ratio in the Pro formulas was selected to leverage both CB1 and CB2 receptor pathways without any THC content.
The entourage effect was first described by Raphael Mechoulam and Shimon Ben-Shabat in 1998 and expanded by Ethan Russo in 2011. The hypothesis proposes that cannabinoids and terpenes act synergistically — with the combined biological activity exceeding what any single compound produces in isolation. Clinical evidence is emerging but not yet definitive
CBD and other cannabinoids are lipophilic molecules that partition into the lipid-rich stratum corneum and diffuse through the skin layers. CB1 and CB2 receptors are expressed in keratinocytes, sebocytes, sensory nerve fibers, and immune cells in the dermis. The carrier system in Kannaco formulas — including the lipid-rich base and functional botanicals — is designed to optimize localized receptor engagement. This is topical delivery, not transdermal: the compounds interact with receptors in the skin and underlying tissue without meaningful systemic absorption.
CB1 receptors are primarily expressed in the central nervous system but are also present in peripheral sensory neurons and skin keratinocytes. In peripheral tissue, CB1 activation may modulate nociceptive signaling locally. CB2 receptors are primarily expressed in immune cells, peripheral tissue, and the skin — including mast cells, macrophages, and keratinocytes. CB2 activation modulates cytokine release and inflammatory signaling. For topical applications, CB2 is the primary target
Topical CBD has a favorable safety profile for concurrent use because systemic absorption is minimal. Unlike oral CBD, topical application does not produce blood levels that would interact with cytochrome P450 enzymes responsible for metabolizing most medications. However, practitioners should always use clinical judgment. For patients on anticoagulants, immunosuppressants, or other medications with narrow therapeutic windows, a brief consultation is appropriate. Kannaco does not make drug interaction claims and recommends practitioners follow standard clinical protocols.
Menthol activates TRPM8 cold receptors in peripheral sensory neurons, producing the cooling sensation. Camphor activates TRPV1 heat receptors at low concentrations, producing the warming sensation that follows. Both are counterirritants — they modulate nociceptive signaling through the gate control mechanism, providing immediate sensory relief while the cannabinoids engage peripheral CB1 and CB2 receptors. This layered mechanism — immediate sensory counterirritant effect followed by cannabinoid receptor engagement — is the basis of the Kannaco formulation philosophy.
The COA from SC Labs (ISO/IEC 17025 accredited) verifies: total cannabinoid potency (CBD, CBG, THC, and all other detected cannabinoids), absence of pesticides (over 60 compounds tested), absence of heavy metals (lead, arsenic, cadmium, mercury), absence of residual solvents, microbial safety (total aerobic count, yeast, mold, E. coli, Salmonella), and water activity. COAs are available on request for every batch. The 0.0% THC result on Pro formulas is verified by this same testing protocol.
Preclinical research supports the presence of CB1 and CB2 receptors in musculoskeletal tissue including tendons, ligaments, and synovial tissue. A 2020 survey study in the European Journal of Pain found that topical CBD use was associated with significant reductions in self-reported pain and improved physical function in arthritis patients. A 2022 study in the Journal of Cannabis Research examined topical CBD for peripheral neuropathy. While large-scale RCTs specific to topical CBD are limited, the mechanistic basis — peripheral CB1/CB2 receptor expression in musculoskeletal tissue — is well established. Kannaco does not make treatment claims based on this research.